Bharat Rasayan Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Tue Apr 14 2026

Bharat Rasayan (NSE: BHARATRAS) Q4 FY26 results are scheduled for May 12, 2026. Trading at Rs 8,200 as of April 2026 — down -34% from its 52-week high of Rs 12,500 — the stock has been on investors’ watchlist ahead of what could be a pivotal quarterly result. This article covers the confirmed results date, analyst consensus estimates, five performance factors, five risks, analyst ratings, and share price outlook for Bharat Rasayan.

Q4 (January-March 2026) is the year’s final quarter, bringing full-year FY26 results, management’s FY27 guidance, and the final dividend recommendation — all from a single board meeting on May 12, 2026.

Get free investment predictions from SEBI-registered analysts on Univest.

Table of Contents

Bharat Rasayan Q4 Results 2026 Date

Bharat Rasayan Q4 FY26 results date is May 12, 2026.

Company	Q4 Results Date	Key Metric to Watch
[object Object]	April 9, 2026	FY27 guidance, deal TCV
[object Object]	April 23, 2026	CC growth guidance
Bharti Airtel	April 29, 2026	ARPU, 5G subscribers
Cipla	May 8, 2026	US generics, biosimilars
Bharat Rasayan	May 12, 2026	See estimates below

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025-26. Bharat Rasayan’s board on May 12, 2026 will approve the full-year FY26 results, consider a final dividend recommendation, and provide the first formal commentary on FY27 business outlook — making this the single most important results event of the year.

Bharat Rasayan Q4 FY26 Earnings Estimates

Bharat Rasayan Q4 FY26 analyst estimates — Revenue, PAT, Margin

Access premium research on Univest.

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Trend
Revenue	Rs 680 Cr	Rs 618 Cr	Sequential recovery expected
Net Profit (PAT)	Rs 55 Cr	Rs 48 Cr	Normalisation expected
Margin	EBITDA 12%	Q3 FY26 level	Improvement target
Volume / Growth	+10% volume YoY	Prior quarter	YoY comparison
Final Dividend	Rs 10	FY26 interim divs	Board decision

Screen Bharat Rasayan live on the Univest Screener. Download the Univest iOS App or Univest Android App for real-time Q4 result alerts.

5 Key Factors Driving Bharat Rasayan Q4 FY26 Performance

1. Agrochemical Market Recovery

Bharat Rasayan produces agrochemical intermediates and technical-grade molecules. The global destocking cycle in agrochemicals is approaching resolution, setting up FY27 as a recovery year.

2. Specialty Molecules Portfolio

The company focuses on niche, higher-margin specialty agrochemical molecules where import competition is less intense than commodity generics.

3. Export Technical Sales

Technical grade exports to global formulators carry higher margins than domestic formulated product sales.

4. R&D and New Molecule Development

Registration of new active ingredients builds competitive advantage and premium pricing.

5. Backward Integration Benefits

In-house manufacturing of key intermediates reduces input cost dependency.

5 Risks to Watch in Bharat Rasayan Q4 FY26

Risk 1: Agro Chemical Destocking Extension

If global channel inventory remains elevated, recovery delays further.

Risk 2: Chinese Competition

Chinese agrochemical producers set aggressive benchmark prices.

Risk 3: Regulatory Approvals

New molecule registration timelines are long and uncertain.

Risk 4: Monsoon Dependency

Domestic demand is correlated with monsoon performance.

Risk 5: Customer Concentration

Large formulators represent significant revenue concentration.

Bharat Rasayan Share Price and Analyst Ratings

Parameter	Value
CMP (April 2026)	Rs 8,200
52-Week High	Rs 12,500
52-Week Low	Rs 7,200
1-Year Return	-34%
Market Cap	Rs 3,600 Cr
NSE Ticker	BHARATRAS
Sector	Agrochemicals

Brokerage	Rating	Target Price	Investment Thesis
Systematix	BUY	Rs 10,500	Specialty molecule portfolio drives margin
Phillip Capital	ADD	Rs 9,800	Agro recovery + export technical growth

Conclusion

Bharat Rasayan Q4 FY26 will reflect specialty agrochemical demand recovery. Revenue above Rs 680 crore and EBITDA margin sustaining above 12% would be a beat. Technical export growth and new molecule registrations are the quality catalysts.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Bharat Rasayan Q4 results 2026 date?

Bharat Rasayan Q4 FY26 results date is May 12, 2026. The board of directors will approve the quarter and full-year FY26 results and consider recommending a final dividend for FY26 shareholders.

Q: What is Bharat Rasayan Q4 FY26 revenue estimate?

Analyst consensus estimate for Bharat Rasayan Q4 FY26 revenue is Rs 680 Cr. Q3 FY26 actual revenue was Rs 618 Cr. Actual Q4 results may differ based on operating conditions.

Q: What is Bharat Rasayan Q4 FY26 PAT estimate?

Analyst consensus estimate for Bharat Rasayan Q4 FY26 net profit (PAT) is Rs 55 Cr. Q3 FY26 actual PAT was Rs 48 Cr.

Q: Will Bharat Rasayan declare a dividend in Q4 FY26?

Bharat Rasayan is expected to declare Rs 10 for FY26, subject to board approval on May 12, 2026 and shareholder approval at the AGM.

Q: What is Bharat Rasayan’s current share price?

Bharat Rasayan is trading at Rs 8,200 as of April 2026, with a 52-week range of Rs 7,200 to Rs 12,500. The 1-year return is -34%.

Q: What were Bharat Rasayan Q3 FY26 results?

In Q3 FY26, Bharat Rasayan reported revenue of Rs 618 Cr and PAT of Rs 48 Cr. Q4 FY26 on May 12, 2026 provides the year-end comparison.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered on Univest Blogs.

Q: Is Bharat Rasayan a good investment ahead of Q4 results?

This article does not constitute investment advice. Bharat Rasayan trades at Rs 8,200 — down -34% from its peak. Consult a SEBI-registered advisor before investing.